New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
- PMID: 24658076
- PMCID: PMC3981911
- DOI: 10.1038/nm.3489
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
Abstract
HIV-1 persists in a latent reservoir despite antiretroviral therapy (ART). This reservoir is the major barrier to HIV-1 eradication. Current approaches to purging the latent reservoir involve pharmacologic induction of HIV-1 transcription and subsequent killing of infected cells by cytolytic T lymphocytes (CTLs) or viral cytopathic effects. Agents that reverse latency without activating T cells have been identified using in vitro models of latency. However, their effects on latently infected cells from infected individuals remain largely unknown. Using a new ex vivo assay, we demonstrate that none of the latency-reversing agents (LRAs) tested induced outgrowth of HIV-1 from the latent reservoir of patients on ART. Using a quantitative reverse transcription PCR assay specific for all HIV-1 mRNAs, we demonstrate that LRAs that do not cause T cell activation do not induce substantial increases in intracellular HIV-1 mRNA in patient cells; only the protein kinase C agonist bryostatin-1 caused significant increases. These findings demonstrate that current in vitro models do not fully recapitulate mechanisms governing HIV-1 latency in vivo. Further, our data indicate that non-activating LRAs are unlikely to drive the elimination of the latent reservoir in vivo when administered individually.
Figures
Similar articles
-
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.J Clin Invest. 2015 May;125(5):1901-12. doi: 10.1172/JCI80142. Epub 2015 Mar 30. J Clin Invest. 2015. PMID: 25822022 Free PMC article.
-
In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7. Retrovirology. 2016. PMID: 27206407 Free PMC article.
-
Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.Antimicrob Agents Chemother. 2015 Oct;59(10):5984-91. doi: 10.1128/AAC.01077-15. Epub 2015 Jul 13. Antimicrob Agents Chemother. 2015. PMID: 26169416 Free PMC article.
-
Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.Cell Host Microbe. 2018 Jan 10;23(1):14-26. doi: 10.1016/j.chom.2017.12.004. Cell Host Microbe. 2018. PMID: 29324227 Free PMC article. Review.
-
CXCR4 Targeting Nanoplatform for Transcriptional Activation of Latent HIV-1 Infected T Cells.ACS Appl Bio Mater. 2024 Aug 19;7(8):4831-4842. doi: 10.1021/acsabm.3c00456. Epub 2023 Aug 16. ACS Appl Bio Mater. 2024. PMID: 37586084 Review.
Cited by
-
Combinatorial Use of Both Epigenetic and Non-Epigenetic Mechanisms to Efficiently Reactivate HIV Latency.Int J Mol Sci. 2021 Apr 2;22(7):3697. doi: 10.3390/ijms22073697. Int J Mol Sci. 2021. PMID: 33918134 Free PMC article. Review.
-
Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation.J Clin Invest. 2020 Sep 1;130(9):4969-4984. doi: 10.1172/JCI137371. J Clin Invest. 2020. PMID: 32573496 Free PMC article.
-
CRISPR/Cas9: a tool to eradicate HIV-1.AIDS Res Ther. 2022 Dec 1;19(1):58. doi: 10.1186/s12981-022-00483-y. AIDS Res Ther. 2022. PMID: 36457057 Free PMC article. Review.
-
Understanding HIV latency: the road to an HIV cure.Annu Rev Med. 2015;66:407-21. doi: 10.1146/annurev-med-092112-152941. Annu Rev Med. 2015. PMID: 25587657 Free PMC article. Review.
-
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals.Sci Transl Med. 2018 Oct 3;10(461):eaau4711. doi: 10.1126/scitranslmed.aau4711. Sci Transl Med. 2018. PMID: 30282696 Free PMC article. Clinical Trial.
References
-
- Finzi D, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295–1300. - PubMed
-
- Wong JK, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291–1295. - PubMed
-
- Siliciano JD, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9:727–728. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical